#ESHCLL2022: GOING VIRTUAL! SAVE THE NEW DATES!

January 14, 2022

ESH 2nd Translational Research Conference
CHRONIC LYMPHOCYTIC LEUKAEMIA

E-CONFERENCE
New dates: March 17-20, 2022
#ESHCLL2022

In view of continuing COVID-19 related challenges and uncertainties,
the ESH 2nd Translational Research Conference on CHRONIC LYMPHOCYTIC LEUKAEMIA
will be held as a VIRTUAL EVENT.

The safety of our speakers and attendees comes first.
We successfully transformed our last 14 conferences into E-Conferences
and will place you in the best dispositions to enjoy the presentations and discussions.

The E-Conference will take place from
Thursday, March 17th to Sunday, March 20th, 2022

REGISTRATION IS OFFERED FOR FREE
as a gesture of solidarity during these difficult times.

STAY TUNED!
Registration opening soon!

EXTENDED DEADLINE FOR ABSTRACT AND CLINICAL CASES
JANUARY 24th, 2022 (23:59 CET)!
DO NOT MISS THE OPPORTUNITY!

Abstracts and clinical cases are eligible to be selected
for an oral or a poster presentation.

ABOUT THE E-CONFERENCE:

The 2^nd ESH TRANSLATIONAL RESEARCH CONFERENCE ON CHRONIC LYMPHOCYTIC LEUKAEMIA is proposing a programme of leading-edge basic and clinical science where a panel of global experts in the field will provide numerous opportunities for formal and informal interactions to discuss the present and the future of CLL research. It is open to an international audience of biologists and clinicians, particularly welcoming those in-training.

This translational research E-Conference will explore the most recent advances in the understanding of the pathogenesis and clinical management of the disease. Open and spirited discussion on the most up-to-date information in the field is expected to understand how the many new biologic insights apply to the future of CLL.

PRELIMINARY PROGRAMME

MEET THE FACULTY

MORE INFORMATION

E-CONFERENCE MAIN TOPICS:
• Spectrum of CLL disease: MBL to Richter’s transformation
• New insights in “old” biomarkers
• Taking driver gene mutations to the next level
• Beyond BcR: other microenvironmental stimuli
• Time-limited therapy
• Covalent BTK inhibitors
• BTK and Bcl2 inhibitor resistance
• Next generation therapies
• The future: other targets

LEARNING OBJECTIVES:
Upon completion of this CME activity, participants should be able to:
• Understand recent advances in elucidating the pathogenesis of CLL
• Describe recent data on the use of prognostic/predictive factors
• Become familiar with the decision-making process for the novel therapeutics for CLL
• Understand emerging data on mechanisms of resistance to targeted agents in CLL
• Understand the debate about how best to optimize CLL therapy in the future

The programme will include:
Plenary Sessions - Panel Discussions
Meet the Expert Sessions - Poster Walk

With the support of*: